We have created a recombinant form of calreticulin (CALR) to serve as an immune adjuvant. For many patients with immunogenically cold tumors, immunotherapies are ineffective. Simulating immunogenic cell death with damage-associated molecular patterns (DAMPs) h... ...

请注册登录后继续浏览